Accelerating our strategic and financial development
AstraZeneca to acquire Alexion
Webinar and conference call for investors and analysts took place on Saturday 12 December 2020 14:00 GMT.
Competition clearances achieved in proposed acquisition of Alexion
Jurisdiction |
Date |
|---|---|
Brazil |
March |
Canada |
March |
Colombia |
March |
Morocco |
April |
Russia |
April |
Turkey |
April |
United States |
April |
Israel |
May |
Japan |
May |
Saudi Arabia |
May |
South Korea |
May |
European Union |
July |
United Kingdom |
July |
-
AstraZeneca to fully acquire Caelum Biosciences
-
Ultomiris approved in the EU for children and adolescents with paroxysmal nocturnal haemoglobinuria
-
ALXN1840 FoCus Phase III trial in Wilson disease met primary endpoint demonstrating improvement in copper mobilisation from tissues
-
Update on CHAMPION-ALS Phase III trial of Ultomiris in amyotrophic lateral sclerosis
-
Pascal Soriot calls for global cooperation in the fight against COVID-19 and climate change
-
Ultomiris recommended for approval in the EU by CHMP for children and adolescents with paroxysmal nocturnal haemoglobinuria
-
Acquisition of Alexion completed
-
AstraZeneca receives final regulatory clearance for the proposed acquisition of Alexion from the UK’s Competition and Markets Authority
, in each case as amended by any subsequent filings made with the SEC. These forward looking statements include all matters that are not historical facts and involve predictions. Forward-looking statements may and often do differ materially from actual results. Any forward-looking statements reflect AstraZeneca’s and Alexion’s current views with respect to future events and are subject to risks relating to future events and other risks, uncertainties and assumptions relating to AstraZeneca’s or Alexion’s results of operations, financial position, liquidity, prospects, growth or strategies and the industries in which they operate. Forward-looking statements speak only as of the date they are made and cannot be relied upon as a guide to future performance. Save as required by law or regulation, AstraZeneca and Alexion disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements in this area of the website, whether as a result of new information, future events or otherwise. Nothing contained in this area of the website should be construed as a profit estimate or profit forecast and no statement in this area of the website should be interpreted to mean that earnings per share of AstraZeneca or Alexion for the current or future financial years would necessarily match or exceed the historical published earnings per share of AstraZeneca or Alexion. Given these risks and uncertainties, investors should not place undue reliance on forward-looking statements as a prediction of actual results.